GlassScriptPhysician profile
Emily Allen
NPI 1174041818
$13,535.91
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $806 · 2022: $2,106 · 2023: $2,967 · 2024: $7,657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,563 · Food and Beverage: $3,514 · Travel and Lodging: $2,244 · Education: $304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,562.50 |
| Food and Beverage | $3,514.45 |
| Travel and Lodging | $2,243.50 |
| Education | $303.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $5,890.65 | 2023-2024 | Jardiance |
| Lilly USA, LLC | $1,876.39 | 2023-2024 | Jardiance |
| Horizon Therapeutics Plc | $905.25 | 2021-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $700.66 | 2022-2024 | |
| Amgen INC. | $652.09 | 2021-2024 | Tavneos, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $633.46 | 2021-2024 | Farxiga |
| Travere Therapeutics, INC. | $486.83 | 2022-2024 | |
| Opko Pharmaceuticals, LLC | $412.28 | 2021-2024 | Rayaldee |
| Glaxosmithkline, LLC. | $336.21 | 2021-2023 | Benlysta |
| Fresenius USA Marketing, INC. | $306.73 | 2021-2023 | Velphoro, Korsuva |
| Otsuka America Pharmaceutical, INC. | $229.24 | 2021-2024 | Jynarque |
| Ani Pharmaceuticals, INC. | $217.48 | 2022-2023 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $208.31 | 2021-2023 | Acthar |
| Vifor Pharma, INC. | $190.52 | 2021-2023 | Veltassa |
| Aurinia Pharma U.S., INC. | $123.89 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $98.35 | 2022-2023 | Tarpeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $83.02 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $73.94 | 2023 | |
| Genzyme Corporation | $56.12 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $30.75 | 2024 | |
| Ardelyx, INC. | $23.74 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.